Duopharma Biotech Berhad (KLSE:DPHARMA)
Malaysia
· Delayed Price · Currency is MYR 1.390
-0.110 (-7.33%)
At close: Mar 9, 2026
Duopharma Biotech Berhad Cash Flow Statement
Financials in millions MYR. Fiscal year is January - December.
Millions MYR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 87.46 | 62.65 | 52.65 | 70.11 | 65.68 | Upgrade
|
| Depreciation & Amortization | 45.62 | 40.58 | 38.76 | 33.48 | 29.66 | Upgrade
|
| Other Amortization | - | 4.81 | 4.29 | 2.72 | 2.29 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.01 | -0.39 | - | - | 0.01 | Upgrade
|
| Asset Writedown & Restructuring Costs | 9.39 | 0.02 | 2.43 | - | 0.1 | Upgrade
|
| Provision & Write-off of Bad Debts | 0.84 | -1.43 | 4.1 | -0.49 | 0.1 | Upgrade
|
| Other Operating Activities | 20.98 | 11.44 | -7.11 | 22.74 | 7.29 | Upgrade
|
| Change in Accounts Receivable | -29.44 | -46.6 | -5.81 | -13.28 | -4.14 | Upgrade
|
| Change in Inventory | -60.67 | -15.35 | -12.39 | -53.36 | -78.43 | Upgrade
|
| Change in Accounts Payable | 32.67 | 27.62 | -28.1 | 8.35 | 20.64 | Upgrade
|
| Operating Cash Flow | 106.84 | 83.34 | 48.8 | 70.27 | 43.2 | Upgrade
|
| Operating Cash Flow Growth | 28.19% | 70.77% | -30.54% | 62.63% | -39.45% | Upgrade
|
| Capital Expenditures | -26.76 | -23.57 | -32.95 | -65.18 | -109.36 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.01 | 0.5 | - | - | 0.02 | Upgrade
|
| Sale (Purchase) of Intangibles | -6.24 | -10.32 | -6.61 | -5.84 | -5.64 | Upgrade
|
| Investment in Securities | - | - | -6.42 | - | -2.07 | Upgrade
|
| Other Investing Activities | 5.87 | 5.97 | 2.75 | 1.52 | 1.2 | Upgrade
|
| Investing Cash Flow | -27.12 | -27.43 | -43.23 | -69.5 | -115.86 | Upgrade
|
| Long-Term Debt Issued | 58.15 | 93.37 | 486.35 | 85.67 | 186.78 | Upgrade
|
| Long-Term Debt Repaid | -78.74 | -128.87 | -369.97 | -59.27 | -89.46 | Upgrade
|
| Net Debt Issued (Repaid) | -20.59 | -35.5 | 116.37 | 26.4 | 97.33 | Upgrade
|
| Common Dividends Paid | -33.67 | -26.93 | -8.85 | -8.2 | -44.96 | Upgrade
|
| Financing Cash Flow | -54.26 | -62.43 | 107.52 | 18.2 | 52.37 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.87 | 0.56 | -0.23 | 0.69 | 0.24 | Upgrade
|
| Net Cash Flow | 26.33 | -5.96 | 112.87 | 19.66 | -20.05 | Upgrade
|
| Free Cash Flow | 80.08 | 59.77 | 15.86 | 5.08 | -66.16 | Upgrade
|
| Free Cash Flow Growth | 33.99% | 276.91% | 211.98% | - | - | Upgrade
|
| Free Cash Flow Margin | 8.60% | 7.35% | 2.25% | 0.73% | -10.35% | Upgrade
|
| Free Cash Flow Per Share | 0.08 | 0.06 | 0.02 | 0.01 | -0.07 | Upgrade
|
| Cash Interest Paid | 24.52 | 27.02 | 21.71 | 16.54 | 11.97 | Upgrade
|
| Cash Income Tax Paid | 17.42 | 10.66 | 16.83 | 24.51 | 11.66 | Upgrade
|
| Levered Free Cash Flow | 51.19 | 31.95 | -10.33 | -6.71 | -60.93 | Upgrade
|
| Unlevered Free Cash Flow | 66.66 | 48.05 | 0.72 | -1.02 | -56.91 | Upgrade
|
| Change in Working Capital | -57.44 | -34.32 | -46.3 | -58.29 | -61.93 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.